Clinical trial · Observational
Connectivity Alterations After Levetiracetam Application
Connectivity Alterations of Brain Network in LGG Patients After Levetiracetam Application at Short Term
NCT04425798CI-TRIAL-00045505unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to analyze the connectivity alterations in brain networks of LGG patients with epilepsy who take levetiracetam at short-term preoperatively.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epilepsy | — | UNRESOLVED | — |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Patients with LEV application
- description
- LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.
- label
- Patients without LEV application
- description
- LGG patients with GRE do not take any medicine or receive any treatment preoperatively.
Primary outcomes (1)
- measure
- The connectivity alterations of brain networks in patients with and without levetiracetam application
- timeFrame
- through study completion, an average of 2 years
- description
- Graph theory analysis is used to delineate topological networks with resting-state functional MRIs and investigated the characteristics of functional networks. Global and nodal topological properties of brain networks are calculated in the two groups of patients. The difference of topological properties of brain networks between patients with and without levetiracetam application are analyzed using t-test or chi-square test according to the type of data.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years; * Histopathological diagnosis with LGG according to the 2016 World Health Organization (WHO) criteria; * Participants received more than 6 years of school education; * Presence of GRE, take levetiracetam less than 1 month; or do not take any medicine and receive any treatment; * No history of biopsy, radiotherapy, or chemotherapy. Exclusion Criteria: * Contraindications for MRI; * Head motion greater than 3 mm in translation or 3° in rotation;
References
Publications (0)
Data not yet available
No reference posted for this study.